Page 84 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $3.70
52wk Low $1.07 Eledon Pharmaceuticals, Inc ELDN $1.27
19900 MacArthur Boulevard
Irvine, CA 92612

(USD - in millions) eledon.com
Market Cap 29.5
Enterprise (29.6)
Basic Shares Out. 24.20 COMPANY OVERVIEW
Float 18.02
Institutional Holdings 17.62% Detailed Analysis:Channelchek.com
Short Interest 0.05
Avg. 90-Day Volume 0.09 Eledon Pharmaceuticals is a clinical stage biotechnology company with
immunology expertise that is developing therapies to protect and
prevent rejection of transplanted organs, as well as to treat
amyotrophic lateral sclerosis (ALS). The Company’s lead compound in
EPS Data development is tegoprubart, an anti-CD40L antibody with high affinity
for CD40 Ligand, a well-validated biological target with broad
2021 2022 2023 therapeutic potential. Eledon is headquartered in Irvine, California.
CQ1 (0.57) (0.69) (0.75)
CQ2 (0.50) (0.65) (0.40)

CQ3 (0.66) (0.73) (0.35)
CQ4 (0.60) (0.68) (0.38)
CY (2.33) (2.75) (1.77) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 3.88
ROE (ttm) -76.66
Debt-to-Total Cap. (mrq) 0.52
Fiscal Year End 31-Dec

19900 MacArt Irvine CA 92612

Key Executives
CEO: Gros, David-Alexandre
CFO: Little, Paul
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures